# Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

> **NCT07102940** · PHASE2 · NOT_YET_RECRUITING · sponsor: **George Washington University** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer
- HER 2 Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- Stage 1-3

## Interventions

- **DRUG:** Eftilagimod Alfa (Efti)
- **DRUG:** Docetaxel-cyclophosphamide (TC) intravenous (i.v)
- **DRUG:** Dose dense Adriamycin-cyclophosphamide (AC) i.v

## Key facts

- **NCT ID:** NCT07102940
- **Lead sponsor:** George Washington University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102940, "Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07102940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*